Project: Programmable Oligo Delivery System for siRNA Prostate cancer thErapy: towards commerciaLization
| Acronym | PROPEL (Reference Number: 114537) |
| Duration | 01/10/2020 - 01/01/2023 |
| Project Topic | PROPEL combines Programmable Oligonucleotide Delivery System (PODS) with next-generation siRNA therapeutic for oncogene silencing and specialized manufacturing to develop a first-in-class therapy for non-metastatic castration resistant prostate cancer (nmCRPC), where there is large unmet need. While the 3 technologies are independently validated by partners, PROPEL benefits from the interdisciplinary expertise of consortium to allow therapy to progress into clinic, expediting commercialization. |
| Network | Eurostars 2 |
| Call | Eurostars Cut–off 13 |
Project partner
| Number | Name | Role | Country |
|---|---|---|---|
| 1 | Uppsala University | Partner | Sweden |
| 2 | BianoGMP | Partner | Germany |
| 3 | Sixfold Bioscience Ltd. | Coordinator | United Kingdom |